Negative predictive value of F-18-FDG coincidence PET in patients with Hodgkin's disease and a residual mass after therapy: A retrospective diagnostic test study

Radiology and Oncology

Volumn 43, Issue 4, 2009, Pages 258-263

  Huić, Dražen ^a   Mutvar, Andrea ^a   Kinda Bašić, Sandra ^a   Aurer, Igor ^a   Ciglar, Martina ^a   Grošev, Darko ^a   Radman, Ivo ^a   Labar, Boris ^a   Dodig, Damir ^a  

^a KBC Zagreb   (Croatia)

Author keywords

FDG; Fluorine 18 fluorodeoxyglucose; Follow up; Hodgkin's disease; Negative predictive value; PET; Prognosis; Therapy monitoring

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; SALVAGE THERAPY; SCHOOL CHILD; SCINTILLATION CAMERA; TREATMENT DURATION;

EID: 71049136520     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-009-0024-x     Document Type: Article

References (25)

1. Israel O, Keidar Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 2004; 3: 166-179
2. Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin N Am 2008; 46: 175-198
3. Hoskin PJ. FDG PET in the management of lymphoma: a clinical perspective. Eur J Nucl Med 2002; 29: 449-451
4. Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-2934
5. Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800. (Pubitemid 34042895)
6. Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, et al. FDG PET in the followup management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after firstline chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 307-315
7. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]- fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-278
8. Nordin AJ, Secondino S, Rahim NA, Pedrazzoli P, Siena S, Rossetti C, et al. Imaging in nasopharyngeal carcinoma: the value of 18-Florine Fluorodeoxyglucose PET/CT in comparison to conventional imaging modalities CT and MRI. Radiol Oncol 2009; 43: 247-257
9. Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Raja Abdullah RSA. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach. Radiol Oncol 2009; 43: 180-186
10. De Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18 FDG - PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.
11. Zijlstra JM, Lindauer-Van Der Werf G, Hoekstra OS, et al. 18 F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91: 522-529
12. Terasawa T, Nihashi T, Hotta T, Nagai H. 18 F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2008; 49: 13-21.
13. Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Hodgkin disease: diagnostic value of FDG PET/CT after first line therapy - is biopsy of FDG - avid lesions still needed? Radiology 2007; 244: 257-262
14. Poulou LS, Karianakis G, Ziakas PD. FDG PET scan strategies and long-term outcomes after firstline therapy in Hodgkin's disease. Eur J Radiol 2009; 70: 499-506.
15. Koga H, Sasaki M, Kuwabara Y, Nakagawa M, Hayashi K, Kaneko K, et al. Lesion detectability of a gamma camera based coincidence system with FDG in patients with malignant tumors: a comparison with dedicated positron emission tomography. Ann Nucl Med 2004; 18: 131-136
16. Ak I, Blokland JA, Pauwels EK, Stokkel MP. The clinical value of 18F-FDG detection with a dualhead coincidence camera: a review. Eur J Nucl Med 2001; 28: 763-778
17. Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non- Hodgkin lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 22-28
18. Schoder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin N Am 2008; 46: 225-241
19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253
20. Grošev D, Lon?ari? S, Vandenberghe S, Dodig D. Triple-head gamma camera PET: system overview and performance characteristics. Nucl Med Commun 2002; 23: 809-814
21. Grošev D. Performance characteristics of gamma cameras - Reply. [Letter] Nucl Med Commun 2003; 24: 440.
22. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advancedstage Hodgkin lymphoma. Blood 2008; 112: 3989-3994
23. Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, et al. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005; 32: 749-756
24. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 2007; 48 Suppl 1:19S-27S.
25. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003; 30: S117-27.